Menu
Search
|

Menu

Close
X

Atossa Genetics Inc ATOS.OQ (NASDAQ Stock Exchange Capital Market)

2.49 USD
+0.00 (+0.00%)
As of Jul 20
chart
Previous Close 2.49
Open 2.49
Volume 8,524
3m Avg Volume 46,559
Today’s High 2.54
Today’s Low 2.45
52 Week High 18.96
52 Week Low 2.03
Shares Outstanding (mil) 11.70
Market Capitalization (mil) 6.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.707
FY17
-16.265
FY16
-26.885
FY15
-68.483
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
1.90
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-240.28
14.61
Return on Equity (TTM)
vs sector
-338.79
16.34

EXECUTIVE LEADERSHIP

Steven Quay
Chairman of the Board, President, Chief Executive Officer, Since
Salary: $500,000.00
Bonus: --
Kyle Guse
Chief Financial Officer, General Counsel, Secretary, Since 2013
Salary: $350,000.00
Bonus: --
Cindy Atha
Vice President of Sales and Marketing, Since 2015
Salary: --
Bonus: --
Janet Rea
Vice President - Regulatory Affairs and Quality, Since 2015
Salary: --
Bonus: --
Shu-Chih Chen
Director, Since 2014
Salary: $224,268.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

107 Spring St
SEATTLE   WA   98104-1005

Phone: +1206.5880256

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

SPONSORED STORIES